<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Amneal Pharmaceuticals</title>
    <link>https://www.biospace.com/employer/3086337/amneal-pharmaceuticals</link>
    <description>Amneal Pharmaceuticals</description>
    <language>en-US</language>
    <lastBuildDate>Mon, 07 Oct 2019 14:08:39 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3086337/amneal-pharmaceuticals.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Recent Job Cuts in the Biopharma Industry</title>
      <link>https://www.biospace.com/recent-job-cuts-in-the-biopharma-industry</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.</description>
      <pubDate>Mon, 07 Oct 2019 14:08:39 GMT</pubDate>
      <guid>https://www.biospace.com/recent-job-cuts-in-the-biopharma-industry</guid>
    </item>
    <item>
      <title>FDA Announces Five Companies Are Recalling Diabetes Drugs Over Carcinogen Concerns</title>
      <link>https://www.biospace.com/fda-announces-five-companies-are-recalling-diabetes-drugs-over-carcinogen-concerns</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.</description>
      <pubDate>Fri, 12 Jun 2020 13:26:26 GMT</pubDate>
      <guid>https://www.biospace.com/fda-announces-five-companies-are-recalling-diabetes-drugs-over-carcinogen-concerns</guid>
    </item>
    <item>
      <title>Kaiser Sues Merck, Generic Drug Firm Over Millions in Losses Due to Alleged "Pay-for-Delay" Scheme</title>
      <link>https://www.biospace.com/kaiser-sues-merck-generic-drug-firm-over-millions-in-losses-due-to-alleged-pay-for-delay-scheme</link>
      <dc:creator>Vanessa Doctor, RN</dc:creator>
      <description>Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a "pay-for-delay" scheme that cost the former millions of dollars.</description>
      <pubDate>Thu, 29 Jul 2021 15:34:17 GMT</pubDate>
      <guid>https://www.biospace.com/kaiser-sues-merck-generic-drug-firm-over-millions-in-losses-due-to-alleged-pay-for-delay-scheme</guid>
    </item>
    <item>
      <title>Amneal Reports Potential Therapeutic Step Forward for Parkinson’s Patients</title>
      <link>https://www.biospace.com/amneal-reports-potential-therapeutic-step-forward-for-parkinson-s-patients</link>
      <dc:creator>Heather McKenzie</dc:creator>
      <description>In the pivotal Phase III trial, Amneal’s investigational Parkinson’s drug, IPX-203, met its primary endpoint, demonstrating superior “Good On” time in patients with motor fluctuations.</description>
      <pubDate>Thu, 26 Aug 2021 13:41:43 GMT</pubDate>
      <guid>https://www.biospace.com/amneal-reports-potential-therapeutic-step-forward-for-parkinson-s-patients</guid>
    </item>
    <item>
      <title>Biosimilars Gain Headway in US with Approval of Kashiv’s Releuko</title>
      <link>https://www.biospace.com/biosimilars-gain-headway-in-the-u-s-with-approval-of-kashiv-s-releuko</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Releuko is expected to launch in the third quarter of 2022 as a treatment for neutropenia, a low white blood cell condition experienced by chemotherapy patients.</description>
      <pubDate>Fri, 11 Mar 2022 15:15:55 GMT</pubDate>
      <guid>https://www.biospace.com/biosimilars-gain-headway-in-the-u-s-with-approval-of-kashiv-s-releuko</guid>
    </item>
    <item>
      <title>Roche Wakes Up to New Competition as FDA Approves Amneal’s Avastin Biosimilar</title>
      <link>https://www.biospace.com/roche-wakes-up-to-new-competition-as-fda-approves-amneal-s-avastin-biosimilar</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.</description>
      <pubDate>Thu, 14 Apr 2022 13:35:37 GMT</pubDate>
      <guid>https://www.biospace.com/roche-wakes-up-to-new-competition-as-fda-approves-amneal-s-avastin-biosimilar</guid>
    </item>
    <item>
      <title>ImmunityBio Backslides while Rigel and Amneal also Reveal Job Cuts (Updated)</title>
      <link>https://www.biospace.com/immunitybio-backslides-while-rigel-and-amneal-also-reveal-job-cuts</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>ImmunityBio is laying off 38 employees at its Dunkirk site in New York, Amneal will shutter a Long Island facility and Rigel culls 30 employees following wAIHA regulatory decision.</description>
      <pubDate>Tue, 11 Oct 2022 14:37:26 GMT</pubDate>
      <guid>https://www.biospace.com/immunitybio-backslides-while-rigel-and-amneal-also-reveal-job-cuts</guid>
    </item>
    <item>
      <title>Reformulated: New Takes on Parkinson’s Disease Treatments</title>
      <link>https://www.biospace.com/reformulated-new-takes-on-parkinson-s-disease-treatments</link>
      <dc:creator>Jia Jie Chen</dc:creator>
      <description>Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.</description>
      <pubDate>Fri, 14 Apr 2023 19:18:54 GMT</pubDate>
      <guid>https://www.biospace.com/reformulated-new-takes-on-parkinson-s-disease-treatments</guid>
    </item>
    <item>
      <title>FDA Action Alert: Regeneron, BioMarin, Eton and Amneal</title>
      <link>https://www.biospace.com/fda-action-alert-regeneron-biomarin-eton-and-amneal</link>
      <dc:creator>Tristan Manalac</dc:creator>
      <description>Regeneron envisions new dosing for Eylea's label and it's the moment of truth for BioMarin's gene therapy for hemophilia A. For that and more, see inside.</description>
      <pubDate>Fri, 23 Jun 2023 12:19:00 GMT</pubDate>
      <guid>https://www.biospace.com/fda-action-alert-regeneron-biomarin-eton-and-amneal</guid>
    </item>
    <item>
      <title>FDA Rejects Amneal’s Extended-Release Parkinson’s Drug</title>
      <link>https://www.biospace.com/fda-rejects-amneal-s-extended-release-parkinson-s-drug</link>
      <dc:creator>Tristan Manalac</dc:creator>
      <description>Citing insufficient safety evidence for one of the drug’s main ingredients, the regulator in a Complete Response Letter rejected the company’s application for Parkinson’s disease candidate IPX203.</description>
      <pubDate>Wed, 05 Jul 2023 13:13:49 GMT</pubDate>
      <guid>https://www.biospace.com/fda-rejects-amneal-s-extended-release-parkinson-s-drug</guid>
    </item>
  </channel>
</rss>
